Stanley Druckenmiller builds Teva place.

Famed US billionaire investor Stanley Druckenmiller’s Duquesne Household Workplace has been shopping for shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) for the previous 4 consecutive quarters. Because the third quarter of 2024, Druckenmiller has bought 16 million shares in Teva together with a million shares within the second quarter of 2025, making it Duquesne’s second greatest holding

Teva once more raises revenue steerage

Analysts see enormous upside in Teva

Israeli institutional buyers wager on Teva

Teva’s inventory is reasonable relative to a really costly inventory market. Whereas the S&P 500’s Shiller a number of has lately approached 39, Teva’s ahead a number of is simply over 6. Teva’s danger versus alternative for Druckenmiller is evident.

Though Teva’s inventory has rebounded previously two years, between 2015 and 2023, shareholders have needed to take care of many challenges. Throughout that point, Teva (looking back) overpaid for generic drugmaker Actavis, which considerably elevated the corporate’s debt, and it has additionally confronted a protracted record of opioid lawsuits (all of which have been settled in early 2023).

However now Teva is rising once more. The corporate’s CEO, Richard Francis, has shifted the corporate’s emphasis towards drug discovery and improvement of branded medicine. Though modern medicine have a restricted exclusivity interval, they provide considerably increased profitability and progress charges in contrast with generic medicine. As well as, main streamlining measures have been applied for the reason that mid-2010s, resulting in a big discount in Teva’s web debt, which might open the door to extra R&D, and maybe additionally to a rise within the earnings a number of.

Printed by Globes, Israel enterprise information – en.globes.co.il – on August 24, 2025.